The number of women who message saying they bought ashwagandha because a wellness influencer made it sound like a cure-all — and then felt worse — is striking. It's not a bad herb. But it's also not a harmless one, and women in perimenopause deserve the full picture before they spend the money.
Learn more about Rose →Adaptogens are plant compounds thought to help the body resist physical and psychological stress by modulating the hypothalamic-pituitary-adrenal (HPA) axis — the system that governs cortisol production. Ashwagandha (Withania somnifera) has the strongest research base of any adaptogen and is the one most likely to show measurable effects on cortisol in clinical settings. That said, 'adaptogen' is not a regulated term, and the quality and dosage of commercial products varies enormously.
Several randomized controlled trials, including a well-cited 2012 study in the Indian Journal of Psychological Medicine and a 2019 study in Medicine, found that ashwagandha root extract (300–600mg daily of KSM-66 or Sensoril extracts) reduced serum cortisol levels by roughly 14–28% compared to placebo in chronically stressed adults. The effect is meaningful for people with genuinely elevated cortisol, but is unlikely to be dramatic for those whose cortisol is already within normal range. Women in perimenopause who have disrupted sleep, high allostatic load, or adrenal dysregulation may be the most likely to notice a real difference.
A 2020 randomized, double-blind, placebo-controlled trial published in PLOS ONE found that ashwagandha root extract (300mg twice daily) significantly improved sleep quality, sleep onset latency, and morning alertness in adults with insomnia. The mechanism is thought to involve triethylene glycol, an active compound in ashwagandha leaves, as well as its downstream effects on cortisol reduction at night. For perimenopausal women whose sleep is disrupted by night sweats and cortisol spikes, this is one of the more credible non-hormonal options worth discussing with a clinician.
Ashwagandha has demonstrated thyroid-stimulating effects in clinical studies — a 2018 study in the Journal of Alternative and Complementary Medicine found it significantly increased T3 and T4 levels in adults with subclinical hypothyroidism. For women who are already on levothyroxine or other thyroid medications, this interaction can push thyroid hormone levels into hyperthyroid territory, causing palpitations, anxiety, weight loss, and insomnia. Anyone with a diagnosed thyroid condition — including Hashimoto's thyroiditis — should get thyroid function tested before starting and during use, and must tell their prescribing doctor.
Ashwagandha is classified as an immune-stimulating herb, meaning it may upregulate immune activity — which is the opposite of what is needed in conditions like lupus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or Hashimoto's thyroiditis. For women whose immune systems are already attacking their own tissue, stimulating further immune activity can worsen symptoms or trigger flares. This is not a theoretical risk — it is a well-established pharmacological property of the herb and is cited as a contraindication in most major herbal pharmacopoeias.
Ashwagandha has traditionally been used in Ayurvedic medicine to induce abortion, and animal studies have confirmed uterine-stimulating (oxytocic) activity at higher doses. While some women in perimenopause assume pregnancy is no longer a concern, irregular cycles make unintended pregnancy possible until 12 consecutive months without a period. Any woman who has not reached confirmed menopause should be aware of this risk.
Ashwagandha has GABAergic activity — meaning it acts on the same neurotransmitter system as benzodiazepines (like diazepam or lorazepam) and many sleep medications. Taking both simultaneously can potentiate sedation, causing excessive drowsiness, impaired coordination, or respiratory depression in vulnerable individuals. Women who are already prescribed anxiolytics, hypnotics, or anti-seizure medications need to discuss this interaction explicitly with their doctor before adding ashwagandha.
A small number of case reports published between 2020 and 2023, including cases in the Journal of Clinical and Experimental Hepatology, have documented drug-induced liver injury (DILI) associated with ashwagandha supplementation. Most cases resolved after discontinuation, but some required medical intervention. The absolute risk appears low, but women with pre-existing liver conditions, those who drink alcohol regularly, or those taking other hepatotoxic medications should treat this as a genuine safety signal rather than a fringe concern.
The trials with the strongest positive results used standardized, concentrated root extracts — most commonly KSM-66 (a full-spectrum root extract standardized to 5% withanolides) or Sensoril (a root and leaf extract) — at doses of 300–600mg daily. Many commercial products use unstandardized root powder with no specified withanolide content, meaning the active compounds may be present in amounts too low to have any measurable effect. Without knowing the extract type and standardization, it is genuinely impossible to know whether a product is likely to do anything at all.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.